← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Arisan Therapeutics, Inc.
Carlsbad, CA
$22,662,095
Total funding
13
Grants
Funding over time
peak $4.8M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,662,095 · 13
By mechanism
R44$7,997,148 · 2
R01$5,459,651 · 1
N01$3,692,037 · 1
R43$3,213,259 · 7
SB1$2,000,000 · 1
R41$300,000 · 1
Investigators at Arisan Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
DEVELOPMENT OF ANTIVIRALS FOR SPECIFIC RNA VIRAL FAMILIES OF PANDEMIC POTENTIAL$3,692,037
N01 · FY2023 · AI
Arenavirus Antiviral Lead Optimization$1,500,000
R44 · FY2016 · AI
Arenavirus Antiviral Lead Optimization$1,500,000
R44 · FY2017 · AI
IND-Enabling Studies for Arenavirus Preclinical Candidate$1,308,008
R01 · FY2021 · AI
IND-Enabling Studies for Arenavirus Preclinical Candidate$1,085,888
R01 · FY2023 · AI
IND-Enabling Studies for Arenavirus Preclinical Candidate$1,085,584
R01 · FY2022 · AI
IND-Enabling Studies for Arenavirus Preclinical Candidate$1,065,105
R01 · FY2024 · AI
Development of a Highly Sensitive Quantitative Rapid Digital LSPR Diagnostic for Acute Dengue and Zika Virus Infection$1,000,000
R44 · FY2020 · AI
Development of a Highly Sensitive Quantitative Rapid Digital LSPR Diagnostic for Acute Dengue and Zika Virus Infection$1,000,000
R44 · FY2019 · AI
Initiation of ARN-75039 API and Drug Product NDA Registration Path and Manufacturing of Phase 3 final Drug Product$1,000,000
SB1 · FY2024 · AI
Initiation of ARN-75039 API and Drug Product NDA Registration Path and Manufacturing of Phase 3 final Drug Product$1,000,000
SB1 · FY2025 · AI
Pre-IND Development of an Arenavirus Antiviral$1,000,000
R44 · FY2020 · AI
Pre-IND Development of an Arenavirus Antiviral$999,816
R44 · FY2021 · AI
Pre-IND Development of an Arenavirus Antiviral$997,332
R44 · FY2022 · AI
IND-Enabling Studies for Arenavirus Preclinical Candidate$915,066
R01 · FY2025 · AI
Identification of novel broad-spectrum Dengue antivirals$449,400
R43 · FY2014 · AI
Optimization of Ebola Virus Entry Inhibitors$350,000
R43 · FY2018 · AI
Ultrasensitive Point-of-Care Diagnostics of Viral Biomarkers and Infectious Diseases$300,000
R41 · FY2016 · AI
Ebola Virus Entry Inhibitors$300,000
R43 · FY2015 · AI
OPTIMIZATION OF NOVEL INFLUENZA M2 CHANNEL INHIBITORS$300,000
R43 · FY2013 · AI